Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC
Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Related Articles
AACR-Sontag Foundation Brain Cancer Research Fellowship
The fellowship provides a two-year grant of $130,000 to support the salary and benefits of the fellow while working on a mentored brain cancer research…
Research and Education Fund Tiered Giving Program – Society of Surgical Oncology
Research and Education Fund Tiered Giving The Research and Education Fund (REF) Tiered Giving Program recognizes donors whose contributions since 2014 have collectively advanced cancer…
FDA Gives Fast Track Designation to VGT-309 for Lung Tumor Visualization
Efficacy findings from a phase 2 trial demonstrated that abenacianine visualized lung tumor tissue and was well tolerated when used during surgery.
From childhood cancer to metabolic syndrome
The prevalence of metabolic syndrome among adult survivors of childhood cancer is higher compared to a noncancer control population. Therapeutic exposures and lifestyle factors are…
Screening Reduces Symptom Burden in Pediatric Cancer Patients – Oncology Nurse Advisor
Study results “provide strong support for integrating symptom screening and care pathways into routine clinical care,” according to researchers
New first‐line treatment improves progression‐free survival for select men with bone mCRPC
Click on the article title to read more.
Ros Atkins on…24 hours on Elon Musk’s X timeline
The BBC’s Analysis editor, Ros Atkins, investigates Elon Musk’s recent posts on X about grooming gangs – and looks at how one day unfolded on…
Cardiovascular toxicities associated with novel cellular immune therapies
Abstract. Over the past decade, T-cell–directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies
Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm
Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.